- Home
- AMS vs NRXS Comparison
AMS vs NRXS Comparison
Compare AMS & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- NRXS
- Stock Information
- Founded
- AMS 1980
- NRXS 2011
- Country
- AMS United States
- NRXS United States
- Employees
- AMS 13
- NRXS N/A
- Industry
- AMS Medical Specialities
- NRXS
- Sector
- AMS Health Care
- NRXS
- Exchange
- AMS Nasdaq
- NRXS Nasdaq
- Market Cap
- AMS 19.3M
- NRXS 17.8M
- IPO Year
- AMS N/A
- NRXS 2023
- Fundamental
- Price
- AMS $3.01
- NRXS $2.31
- Analyst Decision
- AMS
- NRXS
- Analyst Count
- AMS 0
- NRXS 0
- Target Price
- AMS N/A
- NRXS N/A
- AVG Volume (30 Days)
- AMS 4.3K
- NRXS 22.4K
- Earning Date
- AMS 03-26-2025
- NRXS 04-08-2025
- Dividend Yield
- AMS N/A
- NRXS N/A
- EPS Growth
- AMS 779.12
- NRXS N/A
- EPS
- AMS 0.61
- NRXS N/A
- Revenue
- AMS $24,969,000.00
- NRXS $2,456,219.00
- Revenue This Year
- AMS $27.74
- NRXS $383.16
- Revenue Next Year
- AMS $17.72
- NRXS N/A
- P/E Ratio
- AMS $4.96
- NRXS N/A
- Revenue Growth
- AMS 20.83
- NRXS N/A
- 52 Week Low
- AMS $2.51
- NRXS $2.05
- 52 Week High
- AMS $4.60
- NRXS $3.78
- Technical
- Relative Strength Index (RSI)
- AMS 45.88
- NRXS 38.24
- Support Level
- AMS $2.88
- NRXS $2.39
- Resistance Level
- AMS $3.10
- NRXS $2.51
- Average True Range (ATR)
- AMS 0.06
- NRXS 0.15
- MACD
- AMS -0.01
- NRXS -0.03
- Stochastic Oscillator
- AMS 40.33
- NRXS 7.14
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).